← Evidence map

ArticleCancer treatment and research communications2026

Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227].

Ziheng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to "KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status" [Cancer Treatment and Research Communications 47 (2026) 101227]. | OpenQuestion